Navigation Links
Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Date:8/20/2007

of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to fluctuations in our stock price, as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of the Company's most recent Quarterly Report on Form 10-Q on file with the Securities and Exchange Commission. In addition, any forward- looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements.

Quark Pharmaceuticals, Inc. The Ruth Group

Gavin Samuels Stephanie Carrington /

(646) 502-7488 Elizabeth Scott (investors)

GSamuels@quarkpharma.com (646) 536-7017 / 7014

scarrington@theruthgroup.com /

escott@theruthgroup.com

Janine McCargo (media)

(646) 536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 411 More Children Die From Swine Flu 3A CDC 59676 111 More Children Die From Swine Flu 3A CDC 59676 211 More Children Die From Swine Flu 3A CDC 59676 3President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 1President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 2President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 3President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 4President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 5President Barack Obama Joins President George H W Bush to Celebrate the 20th Anniversary of the Points of Light Volunteer Movement and Extend the Cal 59671 6Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 1Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 2Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 3Peregrine Pharmaceuticals Announces Implementation of 1 3A5 Reverse Stock Split to Take Effect October 19 2009 59666 4
Other Medicine Technology:Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7